Literature DB >> 33753542

Higher-Calorie Refeeding in Anorexia Nervosa: 1-Year Outcomes From a Randomized Controlled Trial.

Neville H Golden1, Jing Cheng2, Cynthia J Kapphahn3, Sara M Buckelew4, Vanessa I Machen4, Anna Kreiter3, Erin C Accurso5, Sally H Adams4, Daniel Le Grange5,6, Anna-Barbara Moscicki7, Allyson F Sy3, Leslie Wilson8, Andrea K Garber4.   

Abstract

BACKGROUND AND OBJECTIVES: We recently reported the short-term results of this trial revealing that higher-calorie refeeding (HCR) restored medical stability earlier, with no increase in safety events and significant savings associated with shorter length of stay, in comparison with lower-calorie refeeding (LCR) in hospitalized adolescents with anorexia nervosa. Here, we report the 1-year outcomes, including rates of clinical remission and rehospitalizations.
METHODS: In this multicenter, randomized controlled trial, eligible patients admitted for medical instability to 2 tertiary care eating disorder programs were randomly assigned to HCR (2000 kcals per day, increasing by 200 kcals per day) or LCR (1400 kcals per day, increasing by 200 kcals every other day) within 24 hours of admission and followed-up at 10 days and 1, 3, 6, and 12 months post discharge. Clinical remission at 12 months post discharge was defined as weight restoration (≥95% median BMI) plus psychological recovery. With generalized linear mixed effect models, we examined differences in clinical remission over time.
RESULTS: Of 120 enrollees, 111 were included in modified intent-to-treat analyses, 60 received HCR, and 51 received LCR. Clinical remission rates changed over time in both groups, with no evidence of significant group differences (P = .42). Medical rehospitalization rates within 1-year post discharge (32.8% [19 of 58] vs 35.4% [17 of 48], P = .84), number of rehospitalizations (2.4 [SD: 2.2] vs 2.0 [SD: 1.6]; P = .52), and total number of days rehospitalized (6.0 [SD: 14.8] vs 5.1 [SD: 10.3] days; P = .81) did not differ by HCR versus LCR.
CONCLUSIONS: The finding that clinical remission and medical rehospitalization did not differ over 1-year, in conjunction with the end-of-treatment outcomes, support the superior efficacy of HCR as compared with LCR.
Copyright © 2021 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2021        PMID: 33753542      PMCID: PMC8015147          DOI: 10.1542/peds.2020-037135

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

Review 1.  Atypical Anorexia in Youth: Cautiously Bridging the Treatment Gap.

Authors:  Melissa Freizinger; Michelle Recto; Grace Jhe; Jessica Lin
Journal:  Children (Basel)       Date:  2022-06-05

2.  Sex differences in refeeding among hospitalized adolescents and young adults with eating disorders.

Authors:  Jason M Nagata; Paola Bojorquez-Ramirez; Anthony Nguyen; Kyle T Ganson; Vanessa I Machen; Chloe J Cattle; Sara M Buckelew; Andrea K Garber
Journal:  Int J Eat Disord       Date:  2021-12-26       Impact factor: 5.791

Review 3.  To Improve the Initial Inpatient Management of Adolescents Admitted with Severe Anorexia Nervosa: A Narrative Review and a Convenient Protocol.

Authors:  Stephanie Proulx-Cabana; Marie-Elaine Metras; Danielle Taddeo; Olivier Jamoulle; Jean-Yves Frappier; Chantal Stheneur
Journal:  Nutrients       Date:  2022-01-05       Impact factor: 5.717

Review 4.  Anorexia Nervosa-What Has Changed in the State of Knowledge about Nutritional Rehabilitation for Patients over the Past 10 Years? A Review of Literature.

Authors:  Katarzyna Jowik; Marta Tyszkiewicz-Nwafor; Agnieszka Słopień
Journal:  Nutrients       Date:  2021-10-27       Impact factor: 5.717

5.  [Pediatrics up to date-Brief notes on research].

Authors:  R Kerbl
Journal:  Monatsschr Kinderheilkd       Date:  2021-04-26       Impact factor: 0.323

6.  Rapid refeeding in anorexia nervosa: A dialectic balance.

Authors:  Randolf Staab; Julia Campagna; Julia Ma; Anjana Sengar
Journal:  Int J Eat Disord       Date:  2022-03-25       Impact factor: 5.791

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.